Logo image of GENE

Genetic Technologies Ltd (GENE) Stock Fundamental Analysis

NASDAQ:GENE - Nasdaq - US37185R4065 - ADR - Currency: USD

0.765  -0.02 (-1.92%)

After market: 0.75 -0.02 (-1.96%)

Fundamental Rating

1

GENE gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of GENE have multiple concerns. GENE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GENE has reported negative net income.
In the past year GENE has reported a negative cash flow from operations.
GENE had negative earnings in each of the past 5 years.
GENE had a negative operating cash flow in each of the past 5 years.
GENE Yearly Net Income VS EBIT VS OCF VS FCFGENE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -194.25%, GENE is doing worse than 98.21% of the companies in the same industry.
GENE has a Return On Equity of -656.53%. This is amonst the worse of the industry: GENE underperforms 92.86% of its industry peers.
Industry RankSector Rank
ROA -194.25%
ROE -656.53%
ROIC N/A
ROA(3y)-102.54%
ROA(5y)-75.74%
ROE(3y)-268.4%
ROE(5y)-176.61%
ROIC(3y)N/A
ROIC(5y)N/A
GENE Yearly ROA, ROE, ROICGENE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

With a Gross Margin value of 50.94%, GENE perfoms like the industry average, outperforming 58.93% of the companies in the same industry.
GENE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENE Yearly Profit, Operating, Gross MarginsGENE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

1

2. Health

2.1 Basic Checks

GENE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GENE has been increased compared to 1 year ago.
Compared to 5 years ago, GENE has less shares outstanding
The debt/assets ratio for GENE is higher compared to a year ago.
GENE Yearly Shares OutstandingGENE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
GENE Yearly Total Debt VS Total AssetsGENE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

GENE has an Altman-Z score of -40.90. This is a bad value and indicates that GENE is not financially healthy and even has some risk of bankruptcy.
GENE has a Altman-Z score of -40.90. This is amonst the worse of the industry: GENE underperforms 96.43% of its industry peers.
GENE has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
GENE's Debt to Equity ratio of 0.36 is in line compared to the rest of the industry. GENE outperforms 46.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z -40.9
ROIC/WACCN/A
WACC10.02%
GENE Yearly LT Debt VS Equity VS FCFGENE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 0.88 indicates that GENE may have some problems paying its short term obligations.
GENE has a worse Current ratio (0.88) than 91.07% of its industry peers.
GENE has a Quick Ratio of 0.88. This is a bad value and indicates that GENE is not financially healthy enough and could expect problems in meeting its short term obligations.
GENE's Quick ratio of 0.83 is on the low side compared to the rest of the industry. GENE is outperformed by 87.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.83
GENE Yearly Current Assets VS Current LiabilitesGENE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

GENE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.74%, which is quite good.
GENE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.76%.
GENE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 213.18% yearly.
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.06%
Revenue 1Y (TTM)-11.76%
Revenue growth 3Y299.13%
Revenue growth 5Y213.18%
Sales Q2Q%-18.23%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GENE Yearly Revenue VS EstimatesGENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
GENE Yearly EPS VS EstimatesGENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GENE. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GENE Price Earnings VS Forward Price EarningsGENE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GENE Per share dataGENE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GENE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Genetic Technologies Ltd

NASDAQ:GENE (10/16/2024, 9:36:40 PM)

After market: 0.75 -0.02 (-1.96%)

0.765

-0.02 (-1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-29 2024-08-29
Earnings (Next)N/A N/A
Inst Owners2.68%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.58M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 2.12
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.74
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS1.51
BVpS0.36
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -194.25%
ROE -656.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.94%
FCFM N/A
ROA(3y)-102.54%
ROA(5y)-75.74%
ROE(3y)-268.4%
ROE(5y)-176.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.24
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.83
Altman-Z -40.9
F-Score4
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.69%
Cap/Sales(5y)201.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.06%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.76%
Revenue growth 3Y299.13%
Revenue growth 5Y213.18%
Sales Q2Q%-18.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.45%
OCF growth 3YN/A
OCF growth 5YN/A